Justin Walsh
Stock Analyst at Jones Trading
(1.15)
# 3,538
Out of 4,761 analysts
31
Total ratings
33.33%
Success rate
-10.05%
Average return
Main Sectors:
Stocks Rated by Justin Walsh
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ANRO Alto Neuroscience | Initiates: Buy | $18 | $3.19 | +464.26% | 1 | Dec 16, 2024 | |
| RAPP Rapport Therapeutics | Initiates: Buy | $42 | $12.68 | +231.23% | 1 | Oct 18, 2024 | |
| THTX Theratechnologies | Downgrades: Hold | n/a | $1.85 | - | 2 | Oct 11, 2024 | |
| BLRX BioLineRx | Initiates: Buy | $80 | $3.59 | +2,128.41% | 1 | Sep 4, 2024 | |
| LNTH Lantheus Holdings | Maintains: Buy | $105 → $146 | $78.23 | +86.63% | 7 | Jul 25, 2024 | |
| YMAB Y-mAbs Therapeutics | Initiates: Buy | $23 | $5.72 | +302.10% | 1 | Jul 11, 2024 | |
| CATX Perspective Therapeutics | Maintains: Buy | $15 → $22 | $2.78 | +691.37% | 2 | May 16, 2024 | |
| TLSI TriSalus Life Sciences | Initiates: Buy | $16 | $5.77 | +177.30% | 1 | May 10, 2024 | |
| ACHV Achieve Life Sciences | Initiates: Buy | $20 | $3.17 | +530.91% | 1 | Apr 17, 2024 | |
| CTSO Cytosorbents | Reinstates: Buy | $4 | $1.15 | +247.83% | 4 | Sep 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $20 | $2.97 | +574.54% | 1 | Sep 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $18 | $1.37 | +1,213.87% | 2 | May 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $440 | $5.74 | +7,565.51% | 1 | Feb 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $75 | $1.20 | +6,150.00% | 1 | Oct 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $17 → $20 | $28.95 | -30.92% | 1 | May 20, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $440 → $200 | $3.10 | +6,351.61% | 2 | Apr 5, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $10 | $2.92 | +242.47% | 1 | Jan 19, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $800 | $4.57 | +17,405.47% | 1 | Sep 2, 2021 |
Alto Neuroscience
Dec 16, 2024
Initiates: Buy
Price Target: $18
Current: $3.19
Upside: +464.26%
Rapport Therapeutics
Oct 18, 2024
Initiates: Buy
Price Target: $42
Current: $12.68
Upside: +231.23%
Theratechnologies
Oct 11, 2024
Downgrades: Hold
Price Target: n/a
Current: $1.85
Upside: -
BioLineRx
Sep 4, 2024
Initiates: Buy
Price Target: $80
Current: $3.59
Upside: +2,128.41%
Lantheus Holdings
Jul 25, 2024
Maintains: Buy
Price Target: $105 → $146
Current: $78.23
Upside: +86.63%
Y-mAbs Therapeutics
Jul 11, 2024
Initiates: Buy
Price Target: $23
Current: $5.72
Upside: +302.10%
Perspective Therapeutics
May 16, 2024
Maintains: Buy
Price Target: $15 → $22
Current: $2.78
Upside: +691.37%
TriSalus Life Sciences
May 10, 2024
Initiates: Buy
Price Target: $16
Current: $5.77
Upside: +177.30%
Achieve Life Sciences
Apr 17, 2024
Initiates: Buy
Price Target: $20
Current: $3.17
Upside: +530.91%
Cytosorbents
Sep 7, 2023
Reinstates: Buy
Price Target: $4
Current: $1.15
Upside: +247.83%
Sep 6, 2023
Initiates: Buy
Price Target: $20
Current: $2.97
Upside: +574.54%
May 16, 2023
Initiates: Buy
Price Target: $18
Current: $1.37
Upside: +1,213.87%
Feb 10, 2023
Initiates: Buy
Price Target: $440
Current: $5.74
Upside: +7,565.51%
Oct 7, 2022
Initiates: Buy
Price Target: $75
Current: $1.20
Upside: +6,150.00%
May 20, 2022
Maintains: Buy
Price Target: $17 → $20
Current: $28.95
Upside: -30.92%
Apr 5, 2022
Maintains: Buy
Price Target: $440 → $200
Current: $3.10
Upside: +6,351.61%
Jan 19, 2022
Initiates: Buy
Price Target: $10
Current: $2.92
Upside: +242.47%
Sep 2, 2021
Initiates: Buy
Price Target: $800
Current: $4.57
Upside: +17,405.47%